DK1100529T4 - Thymosin beta 4 fremmer sårheling - Google Patents

Thymosin beta 4 fremmer sårheling

Info

Publication number
DK1100529T4
DK1100529T4 DK99937654.4T DK99937654T DK1100529T4 DK 1100529 T4 DK1100529 T4 DK 1100529T4 DK 99937654 T DK99937654 T DK 99937654T DK 1100529 T4 DK1100529 T4 DK 1100529T4
Authority
DK
Denmark
Prior art keywords
wound healing
promotes wound
thymosin beta
angiogenesis
thymosin
Prior art date
Application number
DK99937654.4T
Other languages
English (en)
Other versions
DK1100529T3 (da
Inventor
Hynda K Kleinman
Allan Goldstein
Katherine M Malinda
Gabriel Sosne
Original Assignee
Us Gov Health & Human Serv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22246605&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1100529(T4) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Us Gov Health & Human Serv filed Critical Us Gov Health & Human Serv
Publication of DK1100529T3 publication Critical patent/DK1100529T3/da
Application granted granted Critical
Publication of DK1100529T4 publication Critical patent/DK1100529T4/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/18—Thymus derived hormone or factor; related peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Silicon Polymers (AREA)
  • Medicinal Preparation (AREA)
DK99937654.4T 1998-07-30 1999-07-29 Thymosin beta 4 fremmer sårheling DK1100529T4 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9469098P 1998-07-30 1998-07-30
PCT/US1999/017282 WO2000006190A1 (en) 1998-07-30 1999-07-29 THYMOSIN β4 PROMOTES WOUND REPAIR

Publications (2)

Publication Number Publication Date
DK1100529T3 DK1100529T3 (da) 2005-12-19
DK1100529T4 true DK1100529T4 (da) 2010-12-20

Family

ID=22246605

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99937654.4T DK1100529T4 (da) 1998-07-30 1999-07-29 Thymosin beta 4 fremmer sårheling

Country Status (11)

Country Link
US (6) US20070111931A9 (da)
EP (3) EP1100529B2 (da)
AT (1) ATE292473T1 (da)
AU (1) AU766826B2 (da)
CA (1) CA2338928A1 (da)
DE (1) DE69924615T3 (da)
DK (1) DK1100529T4 (da)
ES (1) ES2239846T5 (da)
MX (1) MXPA01001041A (da)
PT (1) PT1100529E (da)
WO (1) WO2000006190A1 (da)

Families Citing this family (144)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070191275A1 (en) * 1998-07-30 2007-08-16 Regenerx Biopharmaceuticals, Inc. Method of treating, preventing, inhibiting or reducing damage to cardiac tissue with thymosin beta 4 fragments
AU766826B2 (en) 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
US20070015698A1 (en) * 1998-07-30 2007-01-18 United States Of America As Represented By The Secretary Of Health Treatment of skin, and wound repair, with thymosin beta 4
US20080096817A1 (en) * 1998-07-30 2008-04-24 Regenerx Biopharmaceuticals, Inc. METHODS OF TREATING DISORDERS OF THE EYE AND SURROUNDING TISSUE WITH THYMOSIN BETA 4 (Tbeta4), ANALOGUES, ISOFORMS AND OTHER DERIVATIVES
US20040170625A1 (en) * 1998-07-30 2004-09-02 Regenerx Biopharmaceuticals, Inc. Methods of treating Epidermolysis Bullosa and associated dermatological indications with thymosin beta 4, analogues, isoforms and other derivatives
US6992170B2 (en) 1999-10-15 2006-01-31 Curagen Corporation Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin
US6855806B1 (en) 1999-10-15 2005-02-15 Curagen Corporation Thymosin beta 10-like proteins and nucleic acids encoding same
DE10030149A1 (de) * 2000-06-20 2002-01-10 Switch Biotech Ag Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankungen oder Wundheilung sowie ihre Verwendung zur Identifizierung von pharmakologisch aktiven Substanzen
EP1176200A3 (de) 2000-06-20 2005-01-12 Switch Biotech Aktiengesellschaft Verwendung von Polypeptiden oder diese kodierende Nukleinsäuren zur Diagnose oder Behandlung von Hauterkrankung oder Wundheilung sowie ihre Verwendung zur Indentifizierung von pharmakologisch aktiven Substanzen
FR2814076B1 (fr) * 2000-09-21 2002-12-20 Centre Nat Rech Scient Agent angiogenique et ses utilisations
JP4224297B2 (ja) * 2000-11-02 2009-02-12 リジェナークス・バイオファーマシューティカルズ・インコーポレイテッド アクチン隔離ペプチドによる皮膚老化の阻害又は反転
US20110171333A1 (en) * 2000-12-05 2011-07-14 Bryant Wadsworth Morinda Citrifolia Based Antioxidant and Antimicrobial Formulations for Improved Color Stability and Increased Shelf Life of Various Meat Products
US8652546B2 (en) 2007-09-06 2014-02-18 Tahitian Noni International, Inc. Morinda citrifolia based formulations for regulating T cell immunomodulation in neonatal stock animals
US8790727B2 (en) * 2000-12-05 2014-07-29 Tahitian Noni International, Inc. Morinda citrifolia and iridoid based formulations
US7244463B2 (en) * 2005-10-18 2007-07-17 Tahitian Noni International, Inc. Garcinia mangostana L. enhanced animal food product
US20070196527A1 (en) * 2006-02-23 2007-08-23 Jensen Claude J Preventative and treatment effects of Morinda citrifolia on Osteoarthritis and its related conditions
US6855345B2 (en) * 2001-11-02 2005-02-15 Morinda, Inc. Preventative and treatment effects of Morinda citrifolia on diabetes and its related conditions
US8574642B2 (en) 2000-12-05 2013-11-05 Tahitian Noni International, Inc. Antiviral Morinda citrifolia L. based formulations and methods of administration
US20040192761A1 (en) * 2003-03-25 2004-09-30 Palu Afa Kehaati Preventative and treatment effects of morinda citrifolia as an aromatase inhibitor
US20110217394A1 (en) * 2000-12-05 2011-09-08 Brett Justin West Iridoid Based Formulations
AU2006233251B2 (en) * 2001-03-15 2008-10-02 Regenerx Biopharmaceuticals, Inc. Methods for Treating Disorders of the Eye and Surrounding Tissue with Thymosin Beta4 (TBeta4), Analogues, Isoforms and Other Derivatives
CN100360174C (zh) * 2001-03-15 2008-01-09 雷金纳克斯生物制药公司 胸腺素β4(Tβ4)、类似物、异构体及其它衍生物在制备治疗眼睛和周围组织失调的药物中的应用
JP2005511479A (ja) * 2001-04-17 2005-04-28 モリンダ・インコーポレーテッド モリンダシトリフォリア油および果汁の緩和作用
MXPA03010446A (es) * 2001-05-17 2004-12-06 Regenerx Biopharmaceuticals Composiciones farmaceuticas a base de timosina (4 (t(4), analogos, isorformas y otros derivados para el tratamiento de epidermolisis vesicular hereditaria e indicaciones dermatologicas asociadas, y metodos para esto.
WO2003020215A2 (en) 2001-08-29 2003-03-13 Regenerx Biopharmaceuticals, Inc. Methods of treating mycocardial event related coditions with thymosin beta 4
US7070813B2 (en) * 2001-11-02 2006-07-04 Morinda, Inc. Preventative and treatment effects of morinda citrifolia as a colon cancer cell growth inhibitor
US20110160057A1 (en) * 2001-11-14 2011-06-30 Bryant Wadsworth Morinda Citrifolia Based Antimicrobial Formulations
US7442395B2 (en) * 2002-11-14 2008-10-28 Tahitian Noni International, Inc. Formulation for treating candidiasis using Morinda citrifolia
GB0130608D0 (en) 2001-12-21 2002-02-06 Psimedica Ltd Medical fibres and fabrics
TWI353849B (en) * 2002-01-25 2011-12-11 Us Gov Health & Human Serv Methods and compositions for the promotion of hair
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2008201749B2 (en) * 2002-02-06 2010-05-13 Regenerx Biopharmaceuticals, Inc. Treatment of Infections and Other Disorders
WO2004035008A2 (en) * 2002-02-06 2004-04-29 Regenerx Biopharmaceuticals, Inc. Treatment of infections and other disorders
AU2003223601A1 (en) * 2002-04-12 2003-10-27 King's College London ANTI-INFLAMMATORY AND WOUND HEALING EFFECTS OF LYMPHOID THYMOSIN Beta 4
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
EP1613369A4 (en) * 2003-03-31 2008-10-01 Regenerx Biopharmaceuticals COMPOSITIONS AND METHODS OF DELIVERING THYMOSINE BETA 4, ANALOGUE, ISOFORMS AND OTHER DERIVATIVES
US20060269630A1 (en) * 2003-04-16 2006-11-30 Palu Afa K Morinda citrifolia as a 5-Lipoxygenase inhibitor
JP4073826B2 (ja) * 2003-06-04 2008-04-09 タヒチアン ノニ インターナショナル インコーポレーテッド ヤエヤマアオキの抽出物を含む農業用活力剤
WO2005007118A2 (en) * 2003-07-18 2005-01-27 Regenerx Biopharmaceuticals, Inc. Treatment or prevention of damage due to radiation exposure
US20070259060A1 (en) * 2003-08-12 2007-11-08 Mian-Ying Wang Formulations and Methods for Treating Breast Cancer with Morinda Citrifolia and Methylsulfonymethane
CN1897965A (zh) * 2003-12-22 2007-01-17 雷金纳克斯生物制药公司 反应性的化学剂、生物剂或毒素引起的生物反应或免疫反应的治疗方法或预防方法
JP2007537153A (ja) * 2004-03-05 2007-12-20 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 細胞外基質蓄積の治療または防止
US7531318B2 (en) 2004-08-20 2009-05-12 Board Of Regents, The University Of Texas System Screening of agents for activity against ischemic myocardial insults
AU2005277094A1 (en) * 2004-08-20 2006-03-02 Regenerx Biopharmaceuticals, Inc. Method of treating, preventing, inhibiting or reducing damage to cardiac tissue
WO2006076588A1 (en) * 2005-01-13 2006-07-20 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to a neuro-, muscular- or neuro-muscular-degenerative disease, or restore tissue adversely affected by said disease
US20060204601A1 (en) * 2005-03-09 2006-09-14 Palu Afa K Formulations and methods for preventing and treating substance abuse and addiction
US20060280818A1 (en) * 2005-05-26 2006-12-14 Palu Afa K Nicotinic acetylcholine receptor antagonist
US20070122507A1 (en) * 2005-05-26 2007-05-31 Palu Afa K Histone deacetylase and tumor necrosis factor converting enzyme inhibition
US8383576B2 (en) * 2005-06-17 2013-02-26 Regenerx Biopharmaceuticals, Inc. LKKTET and/or LKKTNT peptide compositions which are lyophilized or in a form capable of being lyophilized
JP5180074B2 (ja) * 2005-07-15 2013-04-10 ベイジン・ノースランド・バイオテック・カンパニー・リミテッド サイモシンβ４誘導体及びその使用方法
WO2007014253A2 (en) * 2005-07-26 2007-02-01 Regenerx Biopharmaceuticals, Inc. Method of treating or preventing tissue deterioration, injury or damage due to congestive heart failure
US20070166417A1 (en) * 2005-11-29 2007-07-19 Palu Afa K Formulation and Methods for Use of Morinda Citrifolia Seed Oil
US20070184137A1 (en) * 2005-11-29 2007-08-09 Palu Afa K Morinda Citrifolia L. Based Formulations for Inhibiting Matrix Metalloproteinase Enzymes
US20070154579A1 (en) * 2005-11-29 2007-07-05 Palu Afa K Morinda Citrifolia Based Formulation And Methods For Weight Management
DK2347775T3 (da) 2005-12-13 2020-07-13 Harvard College Skabeloner til celletransplantation
ES2600806T3 (es) * 2006-01-17 2017-02-10 Regenerx Biopharmaceuticals, Inc. Procedimientos para tratar o prevenir el daño tisular causado por aumento de flujo sanguíneo
US20070281903A1 (en) * 2006-05-04 2007-12-06 Palu Afa K Morinda Citrifolia-Based Formulation 5-LOX And 15-LOX
US8025910B2 (en) 2006-05-12 2011-09-27 Tahitian Noni International, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
US8535741B2 (en) 2006-05-12 2013-09-17 Morinda, Inc. Method and composition for administering bioactive compounds derived from Morinda citrifolia
AU2007288410A1 (en) * 2006-08-18 2008-02-28 Regenerx Biopharmaceuticals, Inc. Methods and compositions for conserving and/or preparing an organ or tissue for transplant
EP2076277A4 (en) * 2006-10-06 2011-06-01 Regenerx Biopharmaceuticals A METHOD FOR TREATING OR PREVENTING DETERIORATION, DAMAGE OR TISSUE DAMAGE DUE TO ORAL MUCOSAL DISEASE OR DISORDER AND / OR REGULATING NF-KAPPAB FALL OR REMOVING NF-KAPPAB ASSISTED ACTIONS
JP5960944B2 (ja) 2006-11-15 2016-08-02 コーダ セラピューティクス， インコーポレイテッド 創傷治癒のための改善された方法および組成物
CA2621452A1 (en) * 2007-02-21 2008-08-21 Innovational Holdings, Llc Stent and method for reducing tissue damage after ischemic injury with thymosin b4
US9770535B2 (en) 2007-06-21 2017-09-26 President And Fellows Of Harvard College Scaffolds for cell collection or elimination
US20080317890A1 (en) * 2007-06-21 2008-12-25 Claude Jarakae Jensen Method for treating visual impairment through the prophylactic administration of a morinda citrifolia-based naturaceutical
WO2009033816A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the combination of thymosin beta 10 and thymosin alpha 1 peptides as a therapeutic agent
US20100184698A1 (en) * 2007-09-11 2010-07-22 Dorian Bevec Use of a deslorelin and mastoparan as a therapeutic agent
KR20100056524A (ko) * 2007-09-11 2010-05-27 몬도바이오테크 래보래토리즈 아게 치료제로서의 펩티드 배합물 티모신 베타 ４ 및 델타 수면 유도 펩티드의 용도
EP2234656A2 (en) 2007-12-21 2010-10-06 Coda Therapeutics, Inc. Improved medical devices
US20090196944A1 (en) * 2008-02-01 2009-08-06 Brad Rawson Methods of Manufacture of Morinda Citrifolia Based Compositions for Treatment of Anti-Inflammatory Diseases through Inhibition of Cox-1, Cox-2, Interleukin -1beta, Interleukin-6, TNF-alpha, HLE, and iNOS
CN102006891B (zh) 2008-02-13 2017-04-26 哈佛学院董事会 连续的细胞程序化装置
US9370558B2 (en) 2008-02-13 2016-06-21 President And Fellows Of Harvard College Controlled delivery of TLR agonists in structural polymeric devices
WO2009146456A1 (en) 2008-05-30 2009-12-03 President And Fellows Of Harvard College Controlled release of growth factors and signaling molecules for promoting angiogenesis
CN101297965B (zh) * 2008-06-16 2011-01-05 浙江省中医药研究院 胸腺肽β4在制备防治支气管哮喘药物中的应用
US8822647B2 (en) 2008-08-26 2014-09-02 City Of Hope Method and compositions using a chimeric antigen receptor for enhanced anti-tumor effector functioning of T cells
CA2756574C (en) * 2009-03-26 2020-01-28 Henry Ford Health System Thymosin .beta.4 for treating neural injury by myelinating damaged neurons
WO2010120749A2 (en) 2009-04-13 2010-10-21 President And Fellow Of Harvard College Harnessing cell dynamics to engineer materials
US8230654B2 (en) 2009-06-10 2012-07-31 Comc, Llc Medallion insert for modular flooring assemblies
US8782989B2 (en) 2009-06-11 2014-07-22 Comc, Llc Narrow lined modular flooring assemblies
US8728456B2 (en) 2009-07-31 2014-05-20 President And Fellows Of Harvard College Programming of cells for tolerogenic therapies
GB2476789A (en) 2009-11-10 2011-07-13 Gl Holdings Inc Bv Use of thymosin for treatment of type 2 diabetes
US20110206786A1 (en) * 2010-02-23 2011-08-25 Brett Justin West Acai and Iridoid Based Formulations
WO2011109834A2 (en) * 2010-03-05 2011-09-09 President And Fellows Of Harvard College Enhancement of skeletal muscle stem cell engrafment by dual delivery of vegf and igf-1
KR101297037B1 (ko) * 2010-03-26 2013-08-14 숙명여자대학교산학협력단 혈관신생촉진용 펩타이드 및 이의 용도
US9693954B2 (en) 2010-06-25 2017-07-04 President And Fellows Of Harvard College Co-delivery of stimulatory and inhibitory factors to create temporally stable and spatially restricted zones
US9504730B2 (en) 2010-09-30 2016-11-29 Regenerx Biopharmaceuticals, Inc. Method of achieving a thymosin beta 4 concentration in a human patient
EP3620185A1 (en) 2010-10-06 2020-03-11 President and Fellows of Harvard College Injectable, pore-forming hydrogels for materials-based cell therapies
WO2012064697A2 (en) 2010-11-08 2012-05-18 President And Fellows Of Harvard College Materials presenting notch signaling molecules to control cell behavior
WO2012126047A1 (en) * 2011-03-18 2012-09-27 Adistem Ltd Agent and method for treating pain and reducing inflammation
EP2701753B1 (en) 2011-04-27 2018-12-26 President and Fellows of Harvard College Cell-friendly inverse opal hydrogels for cell encapsulation, drug and protein delivery, and functional nanoparticle encapsulation
ES2685327T3 (es) 2011-04-28 2018-10-08 President And Fellows Of Harvard College Armazones tridimensionales macroscópicos preformados inyectables para administración mínimamente invasiva
US9675561B2 (en) 2011-04-28 2017-06-13 President And Fellows Of Harvard College Injectable cryogel vaccine devices and methods of use thereof
AU2012261848B2 (en) 2011-06-03 2017-06-15 President And Fellows Of Harvard College In situ antigen-generating cancer vaccine
US20130022687A1 (en) * 2011-07-19 2013-01-24 Fitzgerald Jr John James Topical transdermal method for delivering nutrients through the skin for expedited wound healing
US8632827B2 (en) * 2011-12-13 2014-01-21 Avon Products, Inc Modulation of thymosin beta-4 in skin
KR102060391B1 (ko) * 2011-12-23 2019-12-30 헨리 포드 헬쓰 시스템 말초 신경병증의 회복을 증진시키기 위한 방법, 시스템, 및 조성물
PT2838515T (pt) 2012-04-16 2020-02-25 Harvard College Composições de sílica mesoporosa para modular respostas imunológicas
US8871254B2 (en) 2012-09-19 2014-10-28 Transdermal Biotechnology, Inc. Systems and methods for treatment of acne vulgaris and other conditions with a topical nitric oxide delivery system
US9808654B2 (en) 2013-02-11 2017-11-07 Jan Marini Skin Research Post procedure skin care gel and methods of use thereof
US9339457B2 (en) 2013-03-13 2016-05-17 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9724419B2 (en) 2013-03-13 2017-08-08 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9393265B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9393264B2 (en) 2013-03-13 2016-07-19 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
US9849160B2 (en) 2013-03-13 2017-12-26 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US20140271937A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9320758B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Brain and neural treatments comprising peptides and other compositions
US9314417B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9241899B2 (en) 2013-03-13 2016-01-26 Transdermal Biotechnology, Inc. Topical systems and methods for treating sexual dysfunction
US9687520B2 (en) 2013-03-13 2017-06-27 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US9314433B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Methods and systems for treating or preventing cancer
US9750787B2 (en) 2013-03-13 2017-09-05 Transdermal Biotechnology, Inc. Memory or learning improvement using peptide and other compositions
US20140271731A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Cardiovascular disease treatment and prevention
US9314423B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Hair treatment systems and methods using peptides and other compositions
US9295637B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Compositions and methods for affecting mood states
US20140271938A1 (en) 2013-03-13 2014-09-18 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295647B2 (en) 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Systems and methods for delivery of peptides
US9295636B2 (en) * 2013-03-13 2016-03-29 Transdermal Biotechnology, Inc. Wound healing using topical systems and methods
US9387159B2 (en) 2013-03-13 2016-07-12 Transdermal Biotechnology, Inc. Treatment of skin, including aging skin, to improve appearance
US9314422B2 (en) 2013-03-13 2016-04-19 Transdermal Biotechnology, Inc. Peptide systems and methods for metabolic conditions
US9320706B2 (en) 2013-03-13 2016-04-26 Transdermal Biotechnology, Inc. Immune modulation using peptides and other compositions
DE102013017203A1 (de) * 2013-10-16 2015-04-16 Isa Atay Thymustherapie
EP3137105A4 (en) 2014-04-30 2017-12-27 President and Fellows of Harvard College Combination vaccine devices and methods of killing cancer cells
JP6683686B2 (ja) 2014-08-22 2020-04-22 オークランド ユニサービシーズ リミティド チャネル調節剤
KR101530278B1 (ko) * 2014-09-04 2015-06-24 부산대학교 산학협력단 심근전환유전자 및 심혈관재생유전자를 포함하는 아데노부속바이러스를 유효성분으로 포함하는, 허혈성 심장질환 예방 또는 치료용 조성물
EP3587446A1 (en) 2014-09-19 2020-01-01 City of Hope Costimulatory chimeric antigen receptor t cells targeting il13 r alpha 2
WO2016064078A1 (ko) * 2014-10-22 2016-04-28 주식회사 지트리비앤티 티모신 베타 4를 함유하는 조성물 및 이를 포함하는 약학적 제형
EP3242605A4 (en) 2015-01-06 2018-08-29 CardioVascular BioTherapeutics, Inc. Angiogenic treatment of ischemic heart disease
AU2016205338A1 (en) * 2015-01-06 2017-08-03 Venturis Therapeutics, Inc. Therapeutic angiogenesis for wound healing
HK1247861A1 (zh) 2015-01-30 2018-10-05 President And Fellows Of Harvard College 用於癌症治疗的肿瘤周围和肿瘤内部材料
WO2016133848A2 (en) 2015-02-16 2016-08-25 Cardiovascular Biotherapeutics, Inc. Therapeutic angiogenesis for treating erectile conditions
CN114099793A (zh) 2015-04-10 2022-03-01 哈佛学院院长等 免疫细胞捕获装置及其制备和使用方法
GB2557155B (en) 2015-09-10 2021-03-31 Comc Llc Modular flooring assemblies
JP6996713B2 (ja) 2015-10-06 2022-02-04 エイチエルビー・セラピューティクス・カンパニー・リミテッド チモシンベータ４を含む眼科用製剤の製造方法
CN115487351A (zh) 2016-02-06 2022-12-20 哈佛学院校长同事会 重塑造血巢以重建免疫
CN118078956A (zh) * 2016-05-06 2024-05-28 免疫新炉有限公司 用于受控和持续释放的elp融合蛋白
EP3484448B1 (en) 2016-07-13 2025-04-09 President and Fellows of Harvard College Antigen-presenting cell-mimetic scaffolds and methods for making and using the same
RU2770060C2 (ru) 2016-08-02 2022-04-14 Президент Энд Феллоуз Оф Гарвард Колледж Биологические материалы для модуляции иммунных ответов
KR102340750B1 (ko) 2017-03-03 2021-12-21 에이치엘비테라퓨틱스 주식회사 티모신 베타 4를 유효성분으로 포함하는 안정화된 외용 제제
WO2020061129A1 (en) 2018-09-19 2020-03-26 President And Fellows Of Harvard College Compositions and methods for labeling and modulation of cells in vitro and in vivo
CN110585055B (zh) * 2019-08-26 2023-06-13 武汉贝缇安卡医疗健康投资有限公司 AcSDKP在增加成纤维细胞分泌Ⅲ型胶原蛋白含量的应用
EP4034148A4 (en) 2019-09-23 2025-09-10 Harvard College BIOMATERIAL-BASED ANTIGEN-FREE VACCINE AND ITS USE
CN111249534B (zh) * 2020-01-16 2021-06-15 中国人民解放军总医院 可用于促进创面组织同步修复再生的生物活性支架及其制备方法
AU2021251785A1 (en) 2020-04-07 2022-11-03 Combangio, Inc. Lyophilized mesenchymal stem cell derived secretome and uses thereof
CN111888462B (zh) * 2020-08-10 2022-08-26 中国人民解放军军事科学院军事医学研究院 胸腺素β4在制备微生态平衡调节剂中的应用

Family Cites Families (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261982A (en) * 1977-11-09 1981-04-14 The Procter & Gamble Company Therapeutic composition
US4297276A (en) * 1979-03-23 1981-10-27 Hoffman-La Roche Inc. Thymosin beta 3 and beta 4
US4444757A (en) * 1981-11-16 1984-04-24 Research Corporation Use of thymosin as an anti-diabetes and anti-hypertensive disease agent
US4389343A (en) * 1981-12-24 1983-06-21 Hoffmann-La Roche Inc. Immunopotentiating peptides from thymus
US4388234A (en) * 1981-12-28 1983-06-14 Hoffmann-La Roche Inc. Peptide isolation
FR2530466A1 (fr) 1982-07-21 1984-01-27 Hecmati Michel Gel anti-ride, produit et procede
WO1984002274A1 (en) 1982-12-09 1984-06-21 Hafsten Raymond J Jr Activated, stabilized enzymes useful for wound healing
JPS60500619A (ja) 1983-03-01 1985-05-02 トレンシユ，ル−ドルフ 毛髪処理剤および毛髪処理方法
US4543340A (en) * 1983-04-07 1985-09-24 George Washington University Radioimmunoassay of thymosin β4
GB8330969D0 (en) * 1983-11-21 1983-12-29 Wellcome Found Promoting healing
JPS60142908A (ja) 1983-12-29 1985-07-29 Kanebo Ltd 養毛化粧料
GB8517402D0 (en) * 1985-07-10 1985-08-14 Wellcome Found Treatment of viral infections
US4713394A (en) * 1986-01-17 1987-12-15 Thornfeldt Carl R Treatment of nonacne inflammatory and infectious dermatoses and hair loss
JPS62252711A (ja) 1986-04-24 1987-11-04 Hideharu Tamaki 養毛剤
US4983581A (en) * 1988-05-20 1991-01-08 Institute Of Molecular Biology, Inc. Wound healing composition of IGF-I and TGF-β
US5055447A (en) * 1988-07-28 1991-10-08 Genentech, Inc. Method and compositions for the treatment and prevention of septic shock
JPH02101019A (ja) * 1988-10-05 1990-04-12 Genichiro Soma 抗エイズ剤
JPH02142717A (ja) 1988-11-22 1990-05-31 Kanebo Ltd 養毛化粧料
US5654267A (en) * 1988-12-20 1997-08-05 La Jolla Cancer Research Center Cooperative combinations of ligands contained within a matrix
EP0410348A1 (en) 1989-07-26 1991-01-30 G.D. Searle & Co. Topical spironolactone composition
US5068315A (en) 1990-04-12 1991-11-26 University Of Dundee Composition for the regulation of hair growth
GB9014221D0 (en) 1990-06-26 1990-08-15 Janssen Pharmaceutica Nv Method of treating alopecia
JPH04234325A (ja) * 1990-12-27 1992-08-24 Hoechst Japan Ltd 脳および神経障害治療予防剤
CN1173991C (zh) * 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
US6124259A (en) * 1993-01-28 2000-09-26 Celtrix Pharmaceuticals, Inc. Method for treating ophthalmic disorders with IGFBP
AU6204594A (en) * 1993-02-22 1994-09-14 Ulrich-Christoph Von Arnim Use of heparins for the treatment of inflammatory or immunological diseases
WO1994023739A1 (en) * 1993-04-22 1994-10-27 The George Washington University METHOD OF DECREASING THE TOXICITY OF THERAPEUTIC COMPOSITIONS USING THYMOSIN β¿4?
US5358703A (en) * 1993-09-27 1994-10-25 Mcw Research Foundation, Inc. Method for the detection of nitric oxide
EP0725652A1 (en) * 1993-10-07 1996-08-14 The George Washington University Medical Center METHOD OF TREATING SEPTIC SHOCK USING THYMOSIN $g(b) 4?
US5578570A (en) * 1993-10-07 1996-11-26 The George Washington University Medical Center Method of treating septic shock using thymosin β4
US5593964A (en) * 1993-10-07 1997-01-14 The George Washington University Medical Center Method of treating septic shock by preventing actin polymerization
FR2711060B1 (fr) * 1993-10-13 1995-11-17 Oreal Procédé pour modifier la pousse des poils et/ou des cheveux et compositions utilisables à cet effet.
US5591716A (en) * 1993-11-19 1997-01-07 New York University Beneficial wound healing applications of calreticulin and other hyaluronan-associated proteins
CA2139385C (en) * 1994-02-04 2001-12-25 Gottfried Alber Products containing g-csf and tnf binding protein
US5652209A (en) * 1994-04-29 1997-07-29 University Of Miami Use of secretory products of human lacrimal gland acinar epithelia for tear replacement therapy
FR2719481B1 (fr) 1994-05-05 1996-05-31 Oreal Composition à base de composés antifongiques et de composés antibactériens halogènes pour diminuer la chute des cheveux.
JPH07316022A (ja) 1994-05-24 1995-12-05 Kyowa Hakko Kogyo Co Ltd 育毛剤
JP3202135B2 (ja) 1994-08-10 2001-08-27 カネボウ株式会社 頭髪化粧料
DE19509354A1 (de) * 1994-12-08 1996-06-13 Klett Loch Lore M Kombinationspräparat zur Förderung des Haarwachstums und ggf. des Haut- und Nagelwachstums sowie zur Verhinderung bzw. zur Beseitigung von Haarausfall
FR2741076B1 (fr) * 1995-11-15 1998-01-30 Rech De Pathologie Appliquee S Conjugues peptidiques derives des hormones thymiques, leur utilisation a titre de medicament et compositions les contenant
DE19622422A1 (de) * 1996-06-04 1997-12-11 Sanorell Pharma Gmbh & Co Lagerungsstabile pharmazeutische Zusammensetzung mit immun - modulierenden und antiinflammatorischen Eigenschaften sowie ein Verfahren zu dessen Herstellung
US5663071A (en) * 1996-06-17 1997-09-02 Children's Medical Center Corporation Human thymosin β 15 gene, protein and uses thereof
JP3128203B2 (ja) * 1997-02-10 2001-01-29 一男 坪田 分泌腺細胞とリンパ球との接着阻害剤
DE19711939A1 (de) * 1997-03-21 1998-09-24 Bosch Gmbh Robert Vorrichtung zur Erfassung des Drucks und der Temperatur im Saugrohr einer Brennkraftmaschine
DE19731420A1 (de) * 1997-07-22 1999-01-28 Bosch Gmbh Robert Vorrichtung zur Erfassung des Drucks und der Temperatur im Saugrohr einer Brennkraftmaschine und Verfahren zu ihrer Herstellung
US6030948A (en) 1997-12-19 2000-02-29 Mann; Morris A. Hair regeneration compositions for treatment of alopecia and methods of application related thereto
GB9806632D0 (en) * 1998-03-28 1998-05-27 Stevenson Robert Peptide factor
AU766826B2 (en) * 1998-07-30 2003-10-23 Government of The United States of America, as represented by The Secretary Department of Health & Human Services, The National Institutes of Health, The Thymosin beta4 promotes wound repair
US20040067227A1 (en) * 2001-11-02 2004-04-08 Goldstein Allan L. Inhibition or reversal of skin aging by actin-sequestering peptides
US6586403B1 (en) * 2000-07-20 2003-07-01 Salpep Biotechnology, Inc. Treating allergic reactions and inflammatory responses with tri-and dipeptides
JP4224297B2 (ja) 2000-11-02 2009-02-12 リジェナークス・バイオファーマシューティカルズ・インコーポレイテッド アクチン隔離ペプチドによる皮膚老化の阻害又は反転
US7560280B2 (en) * 2000-11-03 2009-07-14 Kourion Therapeutics Gmbh Human cord blood derived unrestricted somatic stem cells (USSC)
US6821524B2 (en) * 2002-06-03 2004-11-23 Jan Marini Skin Research, Inc. Cosmetic skin care compositions
JP3870918B2 (ja) * 2002-10-23 2007-01-24 株式会社デンソー 温度センサ一体型圧力センサ装置
RU2295963C1 (ru) 2005-10-18 2007-03-27 Закрытое акционерное общество Научно-производственное предприятие "Тринита" Способ получения иммуностимулятора

Also Published As

Publication number Publication date
DE69924615D1 (de) 2005-05-12
US20070111931A9 (en) 2007-05-17
PT1100529E (pt) 2005-10-31
HK1038307A1 (en) 2002-03-15
DE69924615T2 (de) 2006-02-02
WO2000006190A1 (en) 2000-02-10
AU766826B2 (en) 2003-10-23
US20040220111A1 (en) 2004-11-04
US20070009469A1 (en) 2007-01-11
CA2338928A1 (en) 2000-02-10
EP1100529A1 (en) 2001-05-23
DE69924615T3 (de) 2011-05-05
EP1100529B2 (en) 2010-08-25
DK1100529T3 (da) 2005-12-19
EP1591128A1 (en) 2005-11-02
US7268118B2 (en) 2007-09-11
AU5244399A (en) 2000-02-21
US8143218B2 (en) 2012-03-27
US20030060405A1 (en) 2003-03-27
EP2311485A1 (en) 2011-04-20
US20110124550A1 (en) 2011-05-26
ATE292473T1 (de) 2005-04-15
ES2239846T3 (es) 2005-10-01
ES2239846T5 (es) 2011-03-04
EP1100529B1 (en) 2005-04-06
MXPA01001041A (es) 2002-06-04
US20090023663A1 (en) 2009-01-22
US20170326207A1 (en) 2017-11-16

Similar Documents

Publication Publication Date Title
DK1100529T3 (da) Thymosin beta 4 fremmer sårheling
ATE395928T1 (de) Expressionsvektoren und zellinien zur expression von vaskulärem wachstumsfaktor d, sowie verfahren zur behandlung von melanomen
ATE279163T1 (de) Gewebedezellularization
NZ227788A (en) Peptide having growth hormone regulatory effects, and compositions
DE69829858D1 (de) System zum verankern von gewebe an knochen
NO963742L (no) Fremgangsmåte til å stimulere hematopoese med hemaglobin
ATE84420T1 (de) Verfahren zur stimulierung von melanozyten durch lokales anbringen von alpha-msh-analogen, sowie zusammensetzungen.
ATE252639T1 (de) Modifizierter, das dorsalgewebe beeinflussender faktor
CA2321177A1 (en) Recombinant fibronectin-based extracellular matrix for wound healing
DE3787842D1 (de) Mittel zur Behandlung von Arthrosen.
DE69823046D1 (de) Praktische in vitro sialylierung von rekombinanten glykpproteinen
FI874819A7 (fi) Ihmisen yhdistelmä-endoteelisolun kasvutekijä.
DE3781263D1 (de) Peptid-derivate und deren verwendung in der therapie.
DE69837114D1 (de) Oestronsulfamat-Inhibitoren von Oestronsulfatase, pharmazeutischen Zusammensetzungen und Methoden zu ihrer Verwendung
EE9700225A (et) Meetod diabetes mellituse raviks, kasutades KKF
RU2000104878A (ru) Композиция для ухода за кожей
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
ATE368455T1 (de) Verwendung von (+)-tramadol, o-demethyltramadol, o-desmethyl-n-mono-desmethyl-tramadol zur therapie der harninkontinenz
FR2662698B1 (da)
DE69838509D1 (de) Verwendung von rekombinanten menschlichen uteroglobin zur behandlung von fibrotischen krankheitszuständen
FI874676L (fi) Menetelmä anti-HIV:n määrittämiseksi, tarvikkeet sitä varten ja niiden käyttö tässä menetelmässä
DK0471030T3 (da) Glycoproteinhormonreceptormolekyler
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
NO985573L (no) Veksthormonkomponent og ben-antiresorpsjonsmiddel ved syklisk (koherens-) behandling av osteoporose
DE69734349D1 (de) Behandlung von knochenleiden mit adrenomedullin